269 related articles for article (PubMed ID: 26717321)
1. Natural Nuclear Factor Kappa Beta Inhibitors: Safe Therapeutic Options for Inflammatory Bowel Disease.
Tambuwala MM
Inflamm Bowel Dis; 2016 Mar; 22(3):719-23. PubMed ID: 26717321
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases.
Zaidi D; Wine E
Front Pediatr; 2018; 6():317. PubMed ID: 30425977
[TBL] [Abstract][Full Text] [Related]
3. Hydroxylases as therapeutic targets in inflammatory bowel disease.
Cummins EP; Doherty GA; Taylor CT
Lab Invest; 2013 Apr; 93(4):378-83. PubMed ID: 23419710
[TBL] [Abstract][Full Text] [Related]
4. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
Perera AP; Kunde D; Eri R
Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
[TBL] [Abstract][Full Text] [Related]
5. NF-κβ signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities.
Killeen MJ; Linder M; Pontoniere P; Crea R
Drug Discov Today; 2014 Apr; 19(4):373-8. PubMed ID: 24246683
[TBL] [Abstract][Full Text] [Related]
6. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease.
Guo BJ; Bian ZX; Qiu HC; Wang YT; Wang Y
Ann N Y Acad Sci; 2017 Aug; 1401(1):37-48. PubMed ID: 28891095
[TBL] [Abstract][Full Text] [Related]
7. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB in inflammatory bowel disease.
Atreya I; Atreya R; Neurath MF
J Intern Med; 2008 Jun; 263(6):591-6. PubMed ID: 18479258
[TBL] [Abstract][Full Text] [Related]
9. Medical Therapy for Inflammatory Bowel Disease.
Grevenitis P; Thomas A; Lodhia N
Surg Clin North Am; 2015 Dec; 95(6):1159-82, vi. PubMed ID: 26596920
[TBL] [Abstract][Full Text] [Related]
10. Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine.
Bamias G; Arseneau KO; Cominelli F
Curr Opin Gastroenterol; 2017 Nov; 33(6):411-416. PubMed ID: 28901966
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies.
Gambhir S; Vyas D; Hollis M; Aekka A; Vyas A
World J Gastroenterol; 2015 Mar; 21(11):3174-83. PubMed ID: 25805923
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease.
Papoutsopoulou S; Campbell BJ
Curr Pharm Des; 2021; 27(35):3702-3713. PubMed ID: 33602081
[TBL] [Abstract][Full Text] [Related]
13. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease.
Biasi F; Astegiano M; Maina M; Leonarduzzi G; Poli G
Curr Med Chem; 2011; 18(31):4851-65. PubMed ID: 21919842
[TBL] [Abstract][Full Text] [Related]
14. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
Sartor RB
Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
[TBL] [Abstract][Full Text] [Related]
15. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease.
Sreedhar R; Arumugam S; Thandavarayan RA; Karuppagounder V; Watanabe K
Drug Discov Today; 2016 May; 21(5):843-9. PubMed ID: 26995272
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
Hering NA; Schulzke JD
Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
[TBL] [Abstract][Full Text] [Related]
18. Discovery of small-molecule candidates against inflammatory bowel disease.
Bai R; Jie X; Yao C; Xie Y
Eur J Med Chem; 2020 Jan; 185():111805. PubMed ID: 31703817
[TBL] [Abstract][Full Text] [Related]
19. Potential role of nutraceutical compounds in inflammatory bowel disease.
Larussa T; Imeneo M; Luzza F
World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
[TBL] [Abstract][Full Text] [Related]
20. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease.
Ardite E; Panés J; Miranda M; Salas A; Elizalde JI; Sans M; Arce Y; Bordas JM; Fernández-Checa JC; Piqué JM
Br J Pharmacol; 1998 Jun; 124(3):431-3. PubMed ID: 9647464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
